AR030753A1 - Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas - Google Patents

Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas

Info

Publication number
AR030753A1
AR030753A1 ARP010104398A ARP010104398A AR030753A1 AR 030753 A1 AR030753 A1 AR 030753A1 AR P010104398 A ARP010104398 A AR P010104398A AR P010104398 A ARP010104398 A AR P010104398A AR 030753 A1 AR030753 A1 AR 030753A1
Authority
AR
Argentina
Prior art keywords
treat
protein
grogamma
groalfa
viric
Prior art date
Application number
ARP010104398A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR030753A1 publication Critical patent/AR030753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Uso de una cantidad eficaz de un modulador-proteína de IL-8 seleccionado del grupo que consta de un anticuerpo de IL-8, un anticuerpo de receptor de IL-8, un péptido de receptor de IL-8 y un péptido de IL-8 modificado, que es para la manufactura de un medicamento para tratar la sintomatología del resfriado comun causada por infeccion por rhinovirus humano, otros enterovirus, herpesvirus, coronavirus, influenzavirus, parainfluenzavirus, virus respiratorio sincitial, o adenovirus en un ser humano que lo necesite.
ARP010104398A 2000-09-25 2001-09-18 Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas AR030753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23491400P 2000-09-25 2000-09-25

Publications (1)

Publication Number Publication Date
AR030753A1 true AR030753A1 (es) 2003-09-03

Family

ID=22883327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104398A AR030753A1 (es) 2000-09-25 2001-09-18 Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas

Country Status (6)

Country Link
US (1) US20040022762A1 (es)
EP (1) EP1322319A4 (es)
JP (1) JP2004509147A (es)
AR (1) AR030753A1 (es)
AU (1) AU2001294786A1 (es)
WO (1) WO2002024217A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
PL2276505T3 (pl) * 2008-03-20 2014-01-31 Karobio Ab Sprej do nosa lub krople do nosa do leczenia przeziębienia
EP3409277A1 (en) * 2017-05-30 2018-12-05 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment and/or prevention of bacterial secondary infections
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05503512A (ja) * 1989-11-29 1993-06-10 ブリガム・アンド・ウイメンズ・ホスピタル 白血球接着阻害因子としての［ａｌａ　ｉｌ―８］↓７↓７
US5543503A (en) * 1991-03-29 1996-08-06 Genentech Inc. Antibodies to human IL-8 type A receptor
JP3780315B2 (ja) * 1994-03-03 2006-05-31 ジェネンテク・インコーポレイテッド 炎症性疾患の処置のための抗ｉｌ−８モノクローナル抗体
US5890486A (en) * 1996-12-20 1999-04-06 The Procter & Gamble Company Thermal nasal dilator and method of treatment for relief of nasal congestion and other symptoms associated with common cold and allergies
CA2303430A1 (en) * 1997-07-11 1999-01-21 Scherer P. Sanders Nitric oxide inhibits rhinovirus infection
AU2149600A (en) * 1998-11-12 2000-05-29 Musc Foundation For Research Development Methods and compositions for treating common cold symptoms
AR030273A1 (es) * 2000-03-10 2003-08-20 Smithkline Beecham Corp Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina
AR030753A1 (es) * 2000-09-25 2003-09-03 Smithkline Beecham Corp Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas

Also Published As

Publication number Publication date
WO2002024217A1 (en) 2002-03-28
US20040022762A1 (en) 2004-02-05
EP1322319A4 (en) 2005-08-31
JP2004509147A (ja) 2004-03-25
EP1322319A1 (en) 2003-07-02
AU2001294786A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
Clementi et al. Naringenin is a powerful inhibitor of SARS-CoV-2 infection in vitro
Glatthaar-Saalmüller et al. Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret® against viruses causing respiratory infections
EA202193251A1 (ru) Пептидомиметики для лечения коронавирусной и пикорнавирусной инфекций
Vincent et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
CY1121399T1 (el) Σταθεροποιημενες υγρες φαρμακοτεχνικες μορφες αντισωματος αντι-rsv
BR9708517A (pt) Composição farmacêutica processo para prevenir ou tratar doenças mediadas por angiotensina ii em um mamífero e uso de um composto
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
MX2008006851A (es) Materiales y metodos para tratar infecciones virales con un compuesto de cisteamina.
Ferrari et al. Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0511477A (pt) compostos e composições como moduladores de ppar
CY1113182T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης
BR9810745A (pt) Derivados de benzimidazol
NZ520083A (en) The modification of a patient's blood with ultra-violet light for the treatment of congestive heart failure
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
HUP0204333A2 (en) Use of csaids in rhinovirus infection
AR030753A1 (es) Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
Qian et al. Antiviral effect of lithium chloride on replication of avian leukosis virus subgroup J in cell culture
DE69935853D1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
Rubio et al. Survivin prevents apoptosis by binding to caspase-3 in astrocytes infected with the BeAn strain of Theiler’s murine encephalomyelitis virus
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
DE60143078D1 (de) Pax2 zur behandlung von nierenkrankheiten
BRPI0415232A (pt) uso de xenÈnio com hipotermia para tratar asfixia neonatal

Legal Events

Date Code Title Description
FB Suspension of granting procedure